Russian scientists hail results of Covid-19 vaccine trial

Published
12
A larger scale trial, intended to ascertain the strength of the immune response produced by the vaccine and how long protection will last, is expected to begin in Russia in mid-August. —  AP
A larger scale trial, intended to ascertain the strength of the immune response produced by the vaccine and how long protection will last, is expected to begin in Russia in mid-August. — AP

Russian scientists hailed the results of their first clinical trial of a potential coronavirus vaccine on Wednesday, saying it had been proved safe and that volunteers had developed an immune response.

Speaking to a crowded room without wearing masks, three of 18 volunteers monitored over a month at the Sechenov University said they all had experienced few side effects.

A larger scale trial, intended to ascertain the strength of the immune response produced by the vaccine and how long protection will last, is expected to begin in Russia in mid-August.

More than 100 possible vaccines are being developed and tested around the world to try to stop the pandemic.

Of 19 in human trials, only two are in the final Phase III — one by China's Sinopharm and another by AstraZeneca and the University of Oxford.

“We were primarily testing for safety,” Elena Smolyarchuk, a department director at Sechenov University and one of the coordinators of the trial, said.

“On non-specific immunity we can only talk about preliminary results. These show a good, positive tendency, a strengthening of non-specific immunity,” she said.

However, any final conclusions about the immune response among the volunteers will be drawn by the Gamaleya Institute, which developed the vaccine, and are expected towards the end of the month.

Russia's health ministry will then decide whether to register the vaccine and begin a larger scale trial, Smolyarchuk said.

The vaccine is administered in two doses and consists of two serotypes of the human adenovirus, each carrying an S-antigen of the new coronavirus, which enter human cells and produce an immune response, Smolyarchuk said.

It was first tested on primates and then administered to the volunteers on June 18.

"The platform used for the vaccine was developed by Russian scientists over two decades and had formed the basis for several vaccines in the past, including three against Ebola," the Sechenov University's Vadim Tarasov said.

The defence ministry, which conducted a parallel trial of the same vaccine on a separate set of 20 volunteers, also said on Wednesday the group had been discharged.

“It's not scary anymore,” Yuriy, a soldier and volunteer, said in a video shared by the Ministry of Defence.

Opinion

Editorial

Kashmir unresolved
Updated 30 Sep, 2026

Kashmir unresolved

The just solution lies in India addressing the issue through a trilateral dialogue involving the legitimate representatives of the Kashmiri people and Pakistan.
Water shortage
30 Sep, 2026

Water shortage

THAT the country is entering the Rabi season with an anticipated water shortage of nearly 25pc, the lowest carryover...
Young hearts
30 Sep, 2026

Young hearts

THE observance may have passed, but the message of World Heart Day should not fade with it. The occasion is a useful...
Terror and politics
Updated 29 Sep, 2026

Terror and politics

There is an urgent need to tone down the rhetoric and tackle terrorism as a collective challenge for both the affected provinces and the federation.
Watching the glaciers
29 Sep, 2026

Watching the glaciers

THE latest signs from Pakistan’s mountains are worrying. Suparco says the number of unfrozen glacial lakes it...
Dangerous agenda
29 Sep, 2026

Dangerous agenda

AS the world remains fixated on the US-Iran conflict, elsewhere in the Middle East, Israel is consolidating its grip...